Merck KGaA (FRA:MRK)
110.25
+0.75 (0.68%)
Last updated: Nov 10, 2025, 7:10 PM CET
Merck KGaA Revenue
Merck KGaA had revenue of 5.26B EUR in the quarter ending June 30, 2025, a decrease of -1.81%. This brings the company's revenue in the last twelve months to 21.22B, up 1.67% year-over-year. In the year 2024, Merck KGaA had annual revenue of 21.16B with 0.78% growth.
Revenue (ttm)
21.22B
Revenue Growth
+1.67%
P/S Ratio
2.31
Revenue / Employee
335.96K
Employees
59,020
Market Cap
48.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.16B | 163.00M | 0.78% |
| Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
| Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
| Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
| Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
Merck KGaA News
- 5 days ago - Universal Display to buy Oled patent assets from Merck KGaA - Seeking Alpha
- 5 days ago - Universal Display Corporation to Acquire Emissive OLED Patent Assets from Merck KGaA, Darmstadt, Germany - Wallstreet:Online
- 14 days ago - MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies - Financial Post
- 18 days ago - Merck KGaA: An AI-Resistant Pharma Play - Seeking Alpha
- 19 days ago - Merck KGaA (MKKGY) Analyst/Investor Day - Slideshow - Seeking Alpha
- 21 days ago - SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology - Wallstreet:Online
- 25 days ago - Merck KGaA Reaches Deal With U.S. To Cut Prices On IVF Drugs - Nasdaq
- 25 days ago - Merck KGaA (MKGAF) Offers Major IVF Discount in New US Deal - GuruFocus